Immunobiology of sensitization in transplant recipients

American Journal of the Medical Sciences

Volumn 313, Issue 5, 1997, Pages 268-274

  Stadlbauer, Thomas H W ^a   Kupiec Weglinski, Jerzy W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Allograft; Cytokine; Immunoglobulins; Rejection; Transplantation

Indexed keywords

ALLOANTIBODY; COMPLEMENT COMPONENT C3; CYTOKINE; CYTOTOXIC ANTIBODY; FIBRIN; GAMMA INTERFERON; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD TRANSFUSION; COMPLEMENT DEPOSITION; GRAFT REJECTION; HUMAN; IMMUNOBIOLOGY; IMMUNOGLOBULIN DEPOSITION; NONHUMAN; ORGAN TRANSPLANTATION; PASSIVE TRANSPORT; RECIPIENT; SENSITIZATION; SKIN GRAFT;

EID: 0030967583     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199705000-00004     Document Type: Article

References (57)

1. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg. Hyperacute rejection of kidney allografts associated with preexisting humoral antibodies against donor cells. Lancet. 1966;2:662-5.
2. Jordan SC, Yap HK, Sakai RS, Alfonso P, Fichtman M. Hyperacute allograft rejection mediated by anti-vascular endothelial cell antibodies with a negative monocyte crossmatch. Transplantation. 1988;46:585-7.
3. Schuurman HJ, Jambroes GJ, Borleffs JCC, Slootweg PC, Gmelig Meyling FH. Acute humoral rejection after heart transplantation. Transplantation. 1988;46:603-5.
4. Sanfilippo FP, Vaughn WK, Peters TG, Shield CF, Adam PL, Lorber MI, et al. Factors affecting the waiting time of cadaveric kidney transplant candidates in the United States. JAMA. 1992;267:247-52.
5. Dempster WJ. Nature of hyperacute rejection. Br Med J. 1973;1:740-1.
6. Guttmann RD. A genetic survey of rat cardiac allograft rejection in presensitized recipients. Transplantation. 1976; 22:583-8.
7. Medawar PB. Immunity to homologous grafted skin: II. The relationship between the antigens of blood and skin. British Journal of Experimental Pathology. 1946;27:15-24.
8. Simonsen M, Buemann J, Grammeltoft A, Jensen F, Jorgensen K. Biological incompatibility in kidney transplantation in dogs. I. Experimental and morphological investigations. Acta Pathologica et Microbiologica Scandinavica. 1953;32:1-35.
9. Opelz G, Sengar DPS, Mickey MR, Terasaki P. Effect of blood transfusion on subsequent kidney transplantations. Transplant Proc. 1973;5:253-9.
10. Scornik JC, Salomon DR, Howard RJ, Pfaff WW. Prevention of transfusion-induced broad sensitization in renal transplant candidates. Transplantation. 1989;47:617-20.
11. Oluwole SF, Law HT, Reemtsma K, Hardy MA. Effect of ultraviolet-B-irradiated donor-specific blood transfusions and peritransplant immunosuppression with cyclosporine on rat cardiac allograft survival. Transplantation. 1988;45:293-7.
12. Lasek W, Jakobisiak M, Grochowska M, Gorecki D, Gniadecki R, Kalinski P. The influence of pretransplant and posttransplant immunosuppression on cardiac graft survival in the donor-specific transfusion model in mice. Comparison of the effects of cyclophosphamide, procarbazine, cyclosporine and cortisone, Transplantation. 1989;47:913-5.
13. van Rood JJ, Balner H. Blood transfusion and transplantation. Transplantation. 1978;26:275-7.
14. Peugh WN, Wood KJ, Morris PJ. Genetic aspects of blood transfusion effect. Transplantation. 1988;46:438-43.
15. Ruiz P, Coffman TM, Howell DN, Straznickas J, Scroggs MW, Baldwin III WM, et al. Evidence that pretransplant donor blood transfusion prevents rat renal allograft dysfunction but not the in situ cellular alloimmune or morphologic manifestations of rejection. Transplantation. 1988;45:1-7.
16. Perloff LJ, Barker CF. Variable response to donor-specific blood transfusion in the rat. Transplantation, 1984;38:178-82.
17. Cooper DKC, Rose AG, Toit ED, Langmann E, Wicomb WN. Failure of pretransplant third-party and preoperative donor-specific blood transfusion to improve heterotopic cardiac allograft survival in baboons. Transplantation. 1985; 40:569-72.
18. Robbins RC, Sadeghi AM, Kurlansky P, Smith CR, Reemtsma K, Rose EA. Failure of donor-specific pretransplant blood transfusion to prolong heterotopic cardiac allografts in rats. Transplantation. 1987;43:757-8.
19. Sablinski T, Hancock WW, Schmidbauer G, Milford EL, Kupiec-Weglinski JW. CD4 mAb therapy diminishes sensitization to xenoantigen and abrogates hyperacute rejection of hamster cardiac grafts in rats. Transplant Proc. 1992;24:528-30.
20. Madsen JC, Wood KJ, Morris PJ, Effects of anti-L3T4 and anti-LYT2 monoclonal antibody therapy on cardiac allograft survival in presentized recipients. Transplant Proc. 1989; 21:1022.
21. Hall BM, Dorsch SE, Cells mediating allograft rejection. Immunol Rev. 1984;77:31-60.
22. Hardy MA, Oluwole S, Fawwaz R, Satake K, Nowygrod R, Reemtsma K. Selective lymphoid irradiation. III. Prolongation of cardiac xenografts and allografts in presensitized rats. Transplantation. 1982;33:237-42.
23. Hisatake G, Hammond E, Ives M, Griffith J, Shelby J, Eichwald EJ. Hyperacute rejection of the transplanted mouse heart. Transplantation. 1989;47:996-1000.
24. Yasunaga C, Cramer DV, Chapman FA, Wang HK, Barnett M, Wu GD, et al. The prevention of accelerated cardiac allograft rejection in sensitized recipients following treatment with Brequinar sodium. Transplantation. 1993;56: 898-904.
25. DiStefano R, Kupiec-Weglinski JW, Uhteg LC, Puskas J, Araneda D, Diamantstein T, et al. Modulation of accelerated rat cardiac allograft rejection by cyclosporine and ART-18. Transplant Proc. 1988;20:217-22.
26. Hancock W, DiStefano R, Brawn P, Schweitzer RT, Tilney NL, Kupiec-Weglinski JW. Cyclosporine and anti-interlukin 2 receptor monoclonal antibody therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms. Transplantation. 1990;49:416-21.
27. Sablinski T, Sayegh MH, Hancock WW, Kut JP, Kwok CA, Milford EL, et al. Differential role of CD4+ cells in the sensitization and effector phases of accelerated graft rejection. Transplantation. 1991;51:226-31.
28. Shelby J, Wakely E, Jorgensen C, Eichwald JE. Cell-mediated hyperacute rejection. VI. Prolonged survival of heterotopic mouse heart transplants. J Surg Res. 1986;40:133-7.
29. Lund B, Ahrons S. Hyperacute kidney rejection in rabbits with lymphocytotoxic antibodies. Acta Pathologica et Microbiologica Scandinavica. 1970;78:293-7.
30. Kirkman RL, Colvin RB, Flye MW, Williams GM, Sachs DH. Transplantation in miniature swine, VII, Evidence for cellular immune mechanisms in hyperacute rejection of renal allografts. Transplantation. 1979;28:24-30.
31. Rapaport FT, Meek AG, Arnold AN, Miura S, Hayashi R, Strober S. Preoperative preparation of high-risk, specifically hyperimmunized canine renal allograft recipients with total-lymphoid irradiation and cyclosporine. Transplantation. 1987;44:185-95.
32. Bush GJ, Martins ACP, Hollenberg NK, Wilson RE, Colman RW. A primate model of hyperacute renal allograft rejection. Am J Pathol. 1975;79:31-56.
33. Rapaport FT, Converse JM. The immune response to multiple-set skin homografts: An experimental study in men. Ann Surg. 1958;147:273-80.
34. Guttmann RD. In vitro correlates of rejection. I. Suppressive effect and specificity in mixed lymphocyte interaction of alloantiserum producing hyperacute rejection. Transplant Proc. 1977;9:755-60.
35. Forbes RDC, Guttmann RD, Pinto-Blonde M. A passive transfer model of hyperacute rat cardiac allograft rejection. Lab Invest. 1979;41:348-55.
36. Wartenberg J, Milgrom F. In vitro model of hyperacute organ rejection by allotransplantation sera. Transplant Proc. 1979;11:1407-8.
37. Coito AJ, Binder J, de Sousa M, Kupiec-Weglinski JW. The expression of extracellular matrix proteins during accelerated rejection of cardiac allografts in sensitized rats. Transplantation. 1994;57:599-605.
38. Nickerson P, Steurer W, Steiger J, Zheng X, Steele AW, Strom TB. Cytokines and the Thl/Th2 paradigm in transplantation. Curr Opin Immunol. 1994;6:757-64.
39. Der Balian GP, Slack J, Clevinger BL, Bazin H, Davie JM. Subclass restriction of murine antibodies. J Exp Med. 1980;152:209-18.
40. Snapper CM, Peschel C, Paul WE. IFN-τ stimulates IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. J Immunol. 1988;140:2121-7.
41. Finkelman FD, Holmes J, Katona IM, Urban Jr JF, Beckman MP, Park LS, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol. 1990;88:303-33.
42. Kitani A, Strober W. Regulation of Cg subclass germ-line transcripts in human peripheral blood B cells. J Immunol. 1993;151:3478-88.
43. Rashid A, Auchincloss Jr H, Sharon J. Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allogrft survival and suppression of alloantibody production in mice. J Immunol. 1992;148:13828.
44. Binder J, Hancock WW, Watschinger B, Wasowska B, Sayegh MH, Kupiec-Weglinski JW. The alloantibody network following intrathymic immunomodulation of sensitized rat recipients of cardiac allografts. Transplantation. 1995; 59:590-7.
45. Sharma HM, Rosenzweig J, Chatterjee S, Moore S, De Chamlain ML, Platelets in hyperacute reject ion of heterotopic cardiac allografls in presensitized dogs. Am J Pathol. 1973;70:155-74.
46. Amery AH, Pegrum DG, Risdon RA, Williams G. Nature of hyperacute (accelerated, second set) rejection in dog renal allografls and effects of heparin rejection process. Br Med J. 1973;1:455-8.
47. Oluwole SF, Tezueka K, Wasfie T, Stegall MD, Reemtsma K, Hardy MA. Humoral immunity in allograft rejection. The role of cytotoxic alloantibody in hyperacute rejection and enhancement of rat cardiac allografts. Transplantation. 1989;48:751-5.
48. Dempster WJ, Brown DL. The nature of experimenal second-set kidney transplant rejection. 3. The role of complement. British Journal of Experimental Pathology. 1971; 52:280-91.
49. Janoff A, Zeligs JD. Vascular injury and lysis of basement membrane in vitro by neutral protease of human leukocytes. Science. 1968;161:702-4.
50. Venuth MC. Platelet-activating factor: Multifaceted biochemical and physiological mediator. Annual Review of Medical Chemistry. 1985;20:193-215.
51. Handley DA, Van Valen RG, Melden MK, Flury S, Lee ML. Inhibition and reversal of endotoxin-, aggregated IgG-, and PAF-induced hypotension in the rat by SRI 63-702, a PAF receptor antagonist. Immunopharmacology. 1986;12a:11-6.
52. Camussi G. Nielson N, Tetta C, Saunders RN, Milgrom F. Release of platelet-activating factor from rabbit heart perfused in vitro by sera with transplantation alloantibodies. Transplantation. 1987;44:113-8.
53. Dohi K, Tabe Y, Ezaki H. An experimental model for hyperacute rejection in inbred rat cardiac transplantation: Correlation cardiac graft survival time and anti T-cell warm cytotoxic antibody titer. Hiroshima J Mod Sci. 1984;33:251-7.
54. Dohi K, Tabe Y, Ono E, Ezaki H. Relationship between the decrease of cytotoxic antibody with the elapse of time and hyperacute rejection in hyperimmunized rats. Hiroshima J Med Sci. 1985;34:131-6.
55. Schulak JA, Engelstad KM. Humoral presensitization in rat heart allotransplantation. J Surg Res. 1987;42:454-61.
56. Knechtle SJ, Kolbeck PC, Tsuchimoto S, Coundouriotis A, Sanfilippo F, Bollinger RR. Hepatic transplantation into sensitized recipient. Demonstration of hyperacute rejection. Transplantation. 1987;43:8-12.
57. Terada Y, Ueno A. Hyperacute renal allograft in the rabbit Vasoconstriction demonstrated by microangiography. Transplantation. 1983;35:205-8.